首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Palladium(II) complexes with R(2)edda derived ligands. Part IV. O,O'-dialkyl esters of (S,S)-ethylenediamine-N,N'-di-2-(4-methyl)-pentanoic acid dihydrochloride and their palladium(II) complexes: synthesis, characterization and in vitro antitumoral activity against chronic lymphocytic leukemia (CLL) cells.
【24h】

Palladium(II) complexes with R(2)edda derived ligands. Part IV. O,O'-dialkyl esters of (S,S)-ethylenediamine-N,N'-di-2-(4-methyl)-pentanoic acid dihydrochloride and their palladium(II) complexes: synthesis, characterization and in vitro antitumoral activity against chronic lymphocytic leukemia (CLL) cells.

机译:与R(2)edda衍生的配体的钯(II)配合物。第四部分(S,S)-乙二胺-N,N'-二-2-(4-甲基)-戊酸二盐酸盐的O,O'-二烷基酯及其钯(II)配合物:合成,表征和体外抗肿瘤活性对抗慢性淋巴细胞白血病(CLL)细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

Four novel bidentate N,N'-ligand precursors, including O,O'-dialkyl esters (alkyl = ethyl, n-propyl, n-butyl and n-pentyl), L1 x 2 HCl-L4 x 2 HCl, of (S,S)-ethylenediamine-N,N'-di-2-(4-methyl)-pentanoic acid dihydrochloride [(S,S)-H(4)eddl]Cl(2) and the corresponding palladium(II) complexes 1-4, were prepared and characterized by IR, (1)H NMR and (13)C NMR spectroscopy and elemental analysis. In vitro cytotoxicity of all compounds was determined against chronic lymphocytic leukemia cells (CLL). The compounds were found to exhibit higher antitumoral activity than cisplatin. The most active compound 2, [PdCl(2){(S,S)-nPr(2)eddl}], was found to be 13.6 times more active than cisplatin on CLL cells.
机译:(S)的四个新的双齿N,N'-配体前体,包括O,O'-二烷基酯(烷基=乙基,正丙基,正丁基和正戊基),L1 x 2 HCl-L4 x 2 HCl ,S)-乙二胺-N,N'-二-2-(4-甲基)-戊酸二盐酸盐[(S,S)-H(4)eddl] Cl(2)和相应的钯(II)配合物1制备了-4,并通过IR,(1)H NMR和(13)C NMR光谱法和元素分析对其进行了表征。确定了所有化合物对慢性淋巴细胞白血病细胞(CLL)的体外细胞毒性。发现该化合物具有比顺铂更高的抗肿瘤活性。发现活性最高的化合物2 [PdCl(2){(S,S)-nPr(2)eddl}]在CLL细胞上的活性是顺铂的13.6倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号